Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia.
Dmitry LioznovIrina AmosovaSavely A SheetikovKsenia V ZornikovaYana SerdyukGrigory A EfimovMikhail TsyferovMikhail KhmelevskiiAndrei AfanasievNadezhda F KhomyakovaDmitry ZubkovAnton TikhonovTao ZhuLuis BarretoVitalina DzutsevaPublished in: PloS one (2023)
Trial registration: ClinicalTrials.gov: NCT04540419.
Keyphrases
- placebo controlled
- double blind
- phase iii
- phase ii
- study protocol
- clinical trial
- coronavirus disease
- sars cov
- electronic health record
- phase ii study
- big data
- randomized controlled trial
- open label
- gene therapy
- respiratory syndrome coronavirus
- cell free
- machine learning
- squamous cell carcinoma
- deep learning
- radiation therapy
- artificial intelligence